Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 3 Results

Title
Intervention Indication Therapeutic Area Year Actions
Intravenous Doxorubicin Nanoparticles for Advanced Hepatocellular Carcinoma Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2017 View  |  Download
Lurbinectedin in addition to doxorubicin for small-cell lung cancer after prior platinum-containing therapy Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Lurbinectedin (PM01183; Zepzelca) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2020 View  |  Download
Onfekafusp alfa in addition to doxorubicin for advanced or metastatic soft tissue sarcoma – first line Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Onfekafusp alfa (L19-TNF; Fibromun) Soft tissue sarcoma Sarcoma 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications